Trident Texofab's standalone quarterly performance for the period ending December 2023 showed a decrease in net sales by 6.28% and a decrease in net profit by 51.47%. EBITDA also decreased by 31.27%, resulting in a decline in EPS from Rs. 1.14 to Rs. 0.55. The company's shares on BSE closed at Rs. 59.17 on February 15, 2024.